Today, on
Dividend
In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019.
Discharge from liability
The board of directors and the CEO were discharged from liability for the financial year 2019.
Board of directors
Before the AGM it had been proposed re-election of
It was resolved that remuneration to the board of directors will amount to
Auditor
Ernst & Young Aktiebolag was re-elected as auditor, with the authorised public accountant
Authorisation for the board of directors to resolve on new issues of shares
The AGM resolved, in accordance with the board's proposal, on authorization for the board to, on one or more occasions before the next AGM, with or without deviation from the shareholders' pre-emption rights, resolve on new issue of shares. Resolutions on new issue of shares with deviation from the shareholders' pre-emption rights shall be for the following reasons (i) fulfil the Company's equity payment obligation towards
Any share issue with deviation from the shareholders' pre-emption rights resolved upon pursuant to this authorization shall be made at market conditions and the total number of shares that may be issued shall be limited to 20 percent of the outstanding shares as per the date of the notice convening the AGM, of which share issues of up to 10 percent may be carried out for any of the purposes listed in (i) - (iii) above, and up to 10 percent additionally may be used solely for the purpose listed in (iii) above.
Other resolutions
A resolution regarding principles for appointment and instructions for nomination committee was adopted.
For more information, please contact:
Peter Nordkild, CEO,
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
Jakob Dynnes Hansen, CFO,
Phone: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com
Certified Adviser
Phone: +46 8-463 83 00
Mail: certifiedadviser@penser.se
About
We are a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.
https://news.cision.com/asarina-pharma/r/asarina-pharma--resolutions-from-the-annual-general-meeting--5-may-2020,c3104299
https://mb.cision.com/Main/17069/3104299/1242051.pdf
(c) 2020 Cision. All rights reserved., source